Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Int J Mol Sci
2017 Mar 23;184:. doi: 10.3390/ijms18040170.
Show Gene links
Show Anatomy links
Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers.
Luz MC
,
Perez MM
,
Azzalis LA
,
Sousa LV
,
Adami F
,
Fonseca FL
,
Alves BD
.
???displayArticle.abstract???
BACKGROUND: Patients with breast cancer-the deadliest cancer among women-are at constant risk of developing metastasis. Oxidative stress and hypoxia are common feature of tumor cells that can proliferate even in a resultant metabolic acidosis. Despite the low extracellular pH, intracellular pH of tumor cells remains relatively normal, or even more alkaline due to the action of a membrane protein family known as monocarboxylate transporters (MCTs). The objective of this study was to verify the diagnostic and prognostic value of MCT1, MCT4 and CD147 in tumor and peripheral blood samples of patients with breast cancer undergoing chemotherapic treatment.
METHODS: Differential expression of MCT1, MCT4 and CD147 obtained by qPCR was determined by 2-ΔΔCq method between biological samples (tumor and serial samples of peripheral) of patients (n = 125) and healthy women (n = 25).
RESULTS: tumor samples with higher histological grades have shown higher expression of these markers; this higher expression was also observed in blood samples obtained at diagnosis of patients when compared to healthy women and in patients with positive progression of the disease (metastasis development).
CONCLUSION: markers studied here could be a promising strategy in routine laboratory evaluations as breast cancer diagnosis and prognosis.
Figure 1. Graphical representation of the difference in expression of the three markers under study according to the clinical stage. For all three cases, the smallest group of stage samples was used as the calibrator. * Kruskal–Wallis test; 95% confidence interval. p values are related to the CD147 curve.
Figure 2. Graphical representation of expression difference between the patients’ blood samples with positive (green; n = 10) and negative (red; n = 113) progression of the disease. (1) at diagnosis; (2) 3 months after beginning of chemotherapy; and (3) 6 months after beginning of chemotherapy.
Aarøe,
Gene expression profiling of peripheral blood cells for early detection of breast cancer.
2010, Pubmed
Aarøe,
Gene expression profiling of peripheral blood cells for early detection of breast cancer.
2010,
Pubmed
Apostolaki,
Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance.
2007,
Pubmed
Banin Hirata,
Molecular markers for breast cancer: prediction on tumor behavior.
2014,
Pubmed
Bergersen,
Immunogold cytochemistry identifies specialized membrane domains for monocarboxylate transport in the central nervous system.
2002,
Pubmed
Boidot,
Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors.
2012,
Pubmed
Bovenzi,
Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis.
2015,
Pubmed
Choi,
Prognostic significance of lactate/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder.
2014,
Pubmed
Diel,
Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
2000,
Pubmed
Fang,
The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma.
2006,
Pubmed
Froberg,
Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues.
2001,
Pubmed
Gallagher,
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231.
2007,
Pubmed
Halestrap,
The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation.
1999,
Pubmed
Halestrap,
The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond.
2004,
Pubmed
Ignatiadis,
Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
2007,
Pubmed
Jäger,
Serial CEA and CA 15-3 measurements during follow-up of breast cancer patients.
2000,
Pubmed
Kim,
Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses.
2015,
Pubmed
LaBreche,
Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors.
2011,
Pubmed
Lunt,
Aerobic glycolysis: meeting the metabolic requirements of cell proliferation.
2011,
Pubmed
Luporsi,
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.
2012,
Pubmed
Ma,
"Liquid biopsy"-ctDNA detection with great potential and challenges.
2015,
Pubmed
Matos,
The Profile of Heparanase Expression Distinguishes Differentiated Thyroid Carcinoma from Benign Neoplasms.
2015,
Pubmed
Meredith,
Functional and molecular characterisation of lactic acid transport in bovine articular chondrocytes.
2002,
Pubmed
Novaes,
Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors.
1997,
Pubmed
Peng,
MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.
2015,
Pubmed
Pfaffl,
A new mathematical model for relative quantification in real-time RT-PCR.
2001,
Pubmed
Pinheiro,
Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization.
2014,
Pubmed
Pinheiro,
Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.
2008,
Pubmed
Pinheiro,
Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44.
2010,
Pubmed
Pinheiro,
Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.
2010,
Pubmed
Pinheiro,
Role of monocarboxylate transporters in human cancers: state of the art.
2012,
Pubmed
Porporato,
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.
2011,
Pubmed
Ring,
Circulating tumour cells in breast cancer.
2004,
Pubmed
Schneiderhan,
CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models.
2009,
Pubmed
Strati,
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR.
2011,
Pubmed
Swietach,
Regulation of tumor pH and the role of carbonic anhydrase 9.
2007,
Pubmed
Untergasser,
Primer3--new capabilities and interfaces.
2012,
Pubmed
Weidle,
Cancer-related issues of CD147.
2010,
Pubmed
Weigelt,
Breast cancer metastasis: markers and models.
2005,
Pubmed
Zhu,
Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients.
2014,
Pubmed
